KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Intraoperative hypotension is associated with decreased long-term survival in older patients after major noncardiac surgery: Secondary analysis of three randomized trials. PMID 38954871 · J Clin Anesth · 2024-Oct 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Randomized Phase II Trial of Immunotherapy-Based Total Neoadjuvant Therapy for Proficient Mismatch Repair or Microsatellite Stable Locally Advanced Rectal Cancer (TORCH). PMID 38950321 · J Clin Oncol · 2024-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Comparative efficacy of later-line therapies for metastatic colorectal cancer: a network meta-analysis of survival curves. PMID 38845342 · Expert Rev Pharmacoecon Outcomes Res · 2024-Oct The record is a network meta-analysis that synthesizes data from multiple trials. It is not an original formal-result report of a single randomized trial, which is the required evidence type. While it analyzes Phase III trials and includes drug interventions and time-to-event endpoints, its nature as a meta-analysis excludes it from eligibility.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The impact of whole-process visualization collaborative nursing discussions education on perioperative symptoms and emotional well-being in radical prostatectomy patients. PMID 38776055 · Int Urol Nephrol · 2024-Oct The study is a randomized trial in prostate cancer patients but lacks a primary/key secondary time-to-event efficacy endpoint (OS, PFS, etc.) and does not involve a drug-containing intervention. It focuses on a nursing/educational intervention for perioperative symptoms and emotional well-being, which is not a Phase III/IIIb or Phase II/III drug efficacy trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Trilaciclib dosage in Chinese patients with extensive-stage small cell lung cancer: a pooled pharmacometrics analysis. PMID 38760542 · Acta Pharmacol Sin · 2024-Oct This is a pooled pharmacometric analysis of Phase 2/3 trials for a drug (trilaciclib) in oncology (ES-SCLC). While it is human, randomized, and has Phase III components with a drug intervention, it does not report a primary or key secondary time-to-event efficacy endpoint (OS, PFS, etc.) as required for eligibility. The analysis focuses on pharmacokinetics, exposure-response, and safety, not on a key efficacy endpoint like survival or progression-free survival.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Oral leukoplakia treated with laser and scalpel: Interim trial results of recurrence and malignancy. PMID 38654673 · Oral Dis · 2024-Oct The record describes an interim result of a randomized clinical trial for oral leukoplakia (a precancerous condition) comparing laser vs. scalpel. While it is human, randomized, and an original interim result, it lacks explicit Phase III/IIIb designation and does not report a time-to-event efficacy endpoint (OS, PFS, etc.) for a drug-containing intervention. The intervention is non-drug (laser/scalpel). Therefore, it does not meet the core eligibility criteria for inclusion in the oncology KM digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Re: James P. Buteau, Daniel Moon, Michael T. Fahey, et al. Clinical Trial Protocol for PRIMARY2: A Multicentre, Phase 3, Randomised Controlled Trial Investigating the Additive Diagnostic Value of [68Ga]Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Negative or Equivocal Multiparametric Magnetic Resonance Imaging for the Diagnosis of Clinically Significant Prostate Cancer. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.11.008. PMID 38570238 · Eur Urol Oncol · 2024-Oct 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Flexible seamless 2-in-1 design with sample size adaptation. PMID 38549502 · J Biopharm Stat · 2024-Oct The record describes a methodological paper proposing a new adaptive trial design for oncology drug development. It is not an original report of clinical trial results. The abstract discusses design features, simulations, and a case study example, but does not present formal efficacy results (e.g., Kaplan-Meier curves, HR, p-values) from a completed or ongoing randomized trial. The MeSH terms indicate a focus on research design and simulation, not result reporting. Therefore, it is excluded as it is not an original result report and lacks a primary/key time-to-event efficacy endpoint.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Impact of the suprapapillary method on patency in distal malignant biliary obstruction: a multicenter randomized controlled trial. PMID 38521477 · Gastrointest Endosc · 2024-Oct 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Irreversible electroporation to bring initially unresectable locally advanced pancreatic adenocarcinoma to surgery: the IRECAP phase II study. PMID 38494526 · Eur Radiol · 2024-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Impact of Vitamin C on Inflammatory Response and Myocardial Injury in Sepsis Patients. PMID 38401077 · Altern Ther Health Med · 2024-Oct This is a randomized trial of vitamin C in sepsis patients, which is a non-oncology condition. While it is a randomized trial with a drug intervention and reports original results, it does not meet the core oncology eligibility criterion, and the primary endpoint is not a time-to-event efficacy endpoint (e.g., OS, PFS).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Re: Michael S. Hofman, Louise Emmett, Shahneen Sandhu, et al. Overall Survival with [177Lu]Lu-PSMA-617 Versus Cabazitaxel in Metastatic Castration-resistant Prostate Cancer (TheraP): Secondary Outcomes of a Randomised, Open-label, Phase 2 Trial. Lancet Oncol 2024;25:99-107. PMID 38378399 · Eur Urol Oncol · 2024-Oct 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Intensity-modulated radiotherapy alone compared with intensity-modulated radiotherapy plus concurrent chemotherapy in intermediate-risk nasopharyngeal carcinoma : A prospective multicenter phase II trial. PMID 38324078 · Strahlenther Onkol · 2024-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Prostate Virtual High-dose-rate Brachytherapy Boost: 5-Year Results from the PROMETHEUS Prospective Multicentre Trial. PMID 38302321 · Eur Urol Oncol · 2024-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Fluorine-18-labelled Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography or Magnetic Resonance Imaging to Diagnose and Localise Prostate Cancer. A Prospective Single-arm Paired Comparison (PEDAL). PMID 38281891 · Eur Urol Oncol · 2024-Oct The study is a phase III diagnostic imaging trial comparing mpMRI and PSMA-PET/CT for prostate cancer diagnosis. It is single-arm, not randomized, and does not involve a drug-containing therapeutic intervention. The primary endpoints are diagnostic accuracy metrics (sensitivity, specificity, AUC), not time-to-event efficacy outcomes like OS or PFS. Therefore, it does not meet the eligibility criteria for an oncology Kaplan-Meier digitization cohort requiring a randomized drug trial with a time-to-event endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532). PMID 38272747 · Eur Urol Oncol · 2024-Oct 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Quality of life and symptom burden after rectal cancer surgery: a randomised controlled trial comparing patient-led versus standard follow-up. PMID 37395934 · J Cancer Surviv · 2024-Oct The record describes a randomized trial comparing follow-up strategies (patient-led vs. standard) for rectal cancer survivors. While it is a human oncology RCT with original results, it fails key eligibility criteria: (1) No drug-containing intervention is identified; the intervention is a follow-up management strategy, not a drug. (2) The primary endpoint is quality of life (FACT-C score), not a time-to-event efficacy endpoint like OS, PFS, DFS, etc. (3) Without a drug intervention, it cannot meet the core requirement for inclusion in a drug-focused efficacy cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and safety of applying oxidized regenerated cellulose sheets to the parietal pleura of open chest wounds in thoracic surgery: a prospective randomized controlled trial protocol. PMID 39678868 · J Thorac Dis · 2024-Nov-30 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
A qualitative study of attitudes and perceptions of smoking cessation medication among patients with cancer. PMID 39611967 · Support Care Cancer · 2024-Nov-29 This is a secondary qualitative analysis of a randomized tobacco treatment trial embedded in cancer care. It does not report on a primary or key secondary time-to-event efficacy endpoint (like OS, PFS) for a drug intervention in an oncology Phase III/IIIb or Phase II/III randomized trial. The study focuses on patient attitudes and perceptions, not formal efficacy outcomes.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Association of dietary patterns derived by reduced-rank regression with colorectal cancer risk and mortality. PMID 39607503 · Eur J Nutr · 2024-Nov-28 The record describes an oncology, human, randomized trial with a time-to-event primary endpoint (CRC risk and mortality HRs), and reports original results. However, it does not meet the mandatory criterion of a drug-containing intervention (the intervention is a dietary pattern). Therefore, it is excluded.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Multimodal prehabilitation to enhance functional capacity of patients with esophageal cancer during concurrent neoadjuvant chemotherapies-a randomized feasibility trial. PMID 39377252 · Dis Esophagus · 2024-Nov-28 The record describes a randomized feasibility trial in esophageal cancer patients receiving neoadjuvant chemotherapy (drug intervention). It is an original result report. However, the phase is not established as Phase III or IIIb, and the primary/secondary outcomes are feasibility metrics, functional capacity, and quality of life, not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). Therefore, it does not meet the key criterion of having a primary/key secondary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Safety and efficacy of intralesional rituximab injection versus involved site radiation therapy in primary ocular adnexal MALT lymphoma: study protocol for a multicentre randomised controlled trial. PMID 39608989 · BMJ Open · 2024-Nov-27 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Intensive treatment of triple negative breast cancer with residual positive axillary lymph node after neoadjuvant chemotherapy. PMID 39604957 · BMC Womens Health · 2024-Nov-27 Eligible for oncology, human, randomized, drug intervention, time-to-event endpoints, and original result. However, the required phase (III/IIIb or II/III) is not explicitly stated in the provided record, preventing confirmation of eligibility. Metadata indicates 'needs_review' with reason_code 'phase3_evidence_unclear'.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Low-dose tamoxifen treatment reduces collagen organisation indicative of tissue stiffness in the normal breast: results from the KARISMA randomised controlled trial. PMID 39593191 · Breast Cancer Res · 2024-Nov-26 The trial is a Phase II dose-finding trial evaluating a surrogate tissue endpoint (collagen organisation) for tamoxifen in healthy women, not a Phase III definitive efficacy trial with a time-to-event outcome like OS or PFS. It is therefore excluded based on phase and endpoint criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Diagnosis of Incident Cancer After Cryptogenic Stroke: An Exploratory Analysis of the ARCADIA Randomized Trial. PMID 39481070 · Neurology · 2024-Nov-26 The report is an exploratory analysis of incident cancer from a randomized trial (ARCADIA) that is not an oncology trial, does not have a drug intervention, and is not a Phase III/IIIb or Phase II/III cancer drug trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The effect of a virtual educational intervention based on self-efficacy theory on women's skills of breast self- examination. PMID 39587596 · BMC Womens Health · 2024-Nov-25 The study is a randomized, quasi-experimental educational intervention trial for breast self-examination in women, not a Phase III/IIIb or Phase II/III randomized trial of a drug-containing intervention for treating a human malignant neoplasm with a primary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Modified FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type metastatic colorectal cancer: a randomized phase II DEEPER trial. PMID 39587053 · Nat Commun · 2024-Nov-25 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised clinical trial. PMID 39547252 · Lancet · 2024-Nov-23 The record describes a randomized, open-label clinical trial in human oncology patients. It is a phase II/III trial (SU2C-SARC032) with a drug intervention (pembrolizumab) and reports formal primary efficacy results for disease-free survival (a time-to-event endpoint) with hazard ratio and Kaplan-Meier analysis. The trial is not post-hoc, subgroup, or safety-only. All required criteria are explicitly met.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 8 Figure · 11 Panel · risk visible
Influence of Nociception Level Monitor (NOL)-Guided Analgesic Delivery on Perioperative Course in Breast Surgeries: A Randomized Controlled Trial. PMID 39768803 · Medicina (Kaunas) · 2024-Nov-22 The study is a randomized controlled trial in oncology (breast cancer surgery) with a drug intervention (analgesics) and original results. However, it is not a Phase III/IIIb or Phase II/III trial, and its primary endpoint (intraoperative opioid consumption) is a perioperative pain management outcome, not a time-to-event cancer efficacy endpoint (OS, PFS, DFS, etc.). Therefore, it does not meet the criteria for inclusion in the Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of remimazolam besylate versus propofol on haemodynamic profiles in patients undergoing thyroid surgery with recurrent laryngeal nerve monitoring: a protocol for a randomised controlled trial. PMID 39578027 · BMJ Open · 2024-Nov-21 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Genomic profiling and expanded use of targeted anticancer drugs in solid cancers with exhausted evidence-based treatment options (PRECODE): study protocol of a prospective, non-randomized, cohort study. PMID 39574115 · BMC Med Genomics · 2024-Nov-21 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
[Megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early-stage endometrial adenocarcinoma: a prospective study]. PMID 39623260 · Nan Fang Yi Ke Da Xue Xue Bao · 2024-Nov-20 Study is a randomized oncology trial with drug intervention and original results, but it does not report a primary/key secondary time-to-event efficacy endpoint. The outcomes (complete response rate, recurrence rate) are presented as proportions, not survival curves or hazard ratios, and no Kaplan-Meier or time-to-event analysis is described. Phase is not specified as Phase III/IIIb or definitive Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Long term outcomes of intracarotid arterial transfusion of circulatory-derived autologous CD34 + cells for acute ischemic stroke patients-A randomized, open-label, controlled phase II clinical trial. PMID 39568005 · Stem Cell Res Ther · 2024-Nov-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Primary Results of NRG-RTOG1106/ECOG-ACRIN 6697: A Randomized Phase II Trial of Individualized Adaptive (chemo)Radiotherapy Using Midtreatment 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Stage III Non-Small Cell Lung Cancer. PMID 39365957 · J Clin Oncol · 2024-Nov-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma. PMID 39255440 · J Clin Oncol · 2024-Nov-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Patient Reported Outcome Measures in cancer care: a hybrid effectiveness-Implementation trial to optimise Symptom control and health service Experience (PROMISE)-protocol for a randomised controlled trial of electronic self-reporting of symptoms versus usual care during and following treatment in patients with cancer. PMID 39566946 · BMJ Open · 2024-Nov-19 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
It is time to address fear of cancer recurrence in family caregivers: protocol for the feasibility and acceptability of a randomized pilot study of the online version of the Family Caregiver-Fear Of Recurrence Therapy (FC-FORT). PMID 39563465 · Pilot Feasibility Stud · 2024-Nov-19 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
The Effect of Interventions Based on the Information-Motivation-Behavioral Skills Model on the Human Papillomavirus Vaccination Rate Among 11-13-Year-Old Girls in Central and Western China: Protocol for a Randomized Controlled Trial. PMID 39560975 · JMIR Res Protoc · 2024-Nov-19 The record describes a protocol for an RCT, not a report of completed trial results. It lacks original efficacy results and uses a non-time-to-event primary endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Three vs 6 Cycles of Chemotherapy for High-Risk Retinoblastoma: A Randomized Clinical Trial. PMID 39432296 · JAMA · 2024-Nov-19 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Screening for Helicobacter pylori to Prevent Gastric Cancer: A Pragmatic Randomized Clinical Trial. PMID 39348147 · JAMA · 2024-Nov-19 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Survival outcomes of population-wide colonoscopy screening: reanalysis of the NordICC data. PMID 39558249 · BMC Gastroenterol · 2024-Nov-18 The study is a secondary reanalysis of an existing trial (NordICC) and does not involve a drug intervention, failing two key eligibility criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The Effect of Vitamin D Supplementation on Quality of Life in Stage II-III Colorectal Cancer Patients Undergoing Adjuvant Chemotherapy: A Single-Blind, Randomized Controlled Trial. PMID 39557774 · J Gastrointest Cancer · 2024-Nov-18 The report is an oncology, human, randomized trial with an original primary result. However, it is excluded because it lacks a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.). The primary endpoint is quality of life, which is a patient-reported outcome, not a time-to-event efficacy measure. Additionally, the intervention is a dietary supplement (vitamin D), not a systemic anti-cancer drug meeting the 'drug-containing intervention' criterion for oncology efficacy trials.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
High-dose vitamin D supplementation does not improve outcome in a cutaneous melanoma population: results of a randomized double-blind placebo-controlled study (ViDMe trial). PMID 38913652 · Br J Dermatol · 2024-Nov-18 The study is a randomized, controlled trial in oncology with a time-to-event primary endpoint and reports original results, but the intervention is a dietary supplement (vitamin D), not a drug, and the trial phase is not specified as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of ultrasound-guided individualized positive end-expiratory pressure on the severity of postoperative atelectasis in elderly patients: a randomized controlled study. PMID 39548165 · Sci Rep · 2024-Nov-15 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
High Mechanical Conditioning by Tumor Extracellular Matrix Stiffness Is a Predictive Biomarker for Antifibrotic Therapy in HER2-Negative Breast Cancer. PMID 39283720 · Clin Cancer Res · 2024-Nov-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial. PMID 39250635 · Clin Cancer Res · 2024-Nov-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
FDA Approval Summary: Belzutifan for Patients with Advanced Renal Cell Carcinoma. PMID 39248780 · Clin Cancer Res · 2024-Nov-15 The record is an FDA approval summary for belzutifan, reporting primary results from the definitive Phase III LITESPARK-005 trial. All required criteria are explicitly established: oncology (renal cell carcinoma), human, randomized, Phase III (definitive), time-to-event efficacy endpoint (PFS), drug intervention (belzutifan), and original trial result. The report type is primary (initial results of the trial).
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Memantine to Reduce Cognitive Impairment After Radiation in Children: A Pilot Study Evaluating the Feasibility of Memantine in Reducing Cognitive Impairment in Pediatric Patients after Radiation Therapy for Central Nervous System Tumors. PMID 39001719 · Int J Radiat Oncol Biol Phys · 2024-Nov-15 The record describes a single-arm, non-randomized Phase III-referencing feasibility study with a primary endpoint of drug adherence, not a time-to-event efficacy endpoint. While it involves oncology, humans, and a drug intervention, it fails the randomized trial and time-to-event endpoint criteria.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Long-term outcomes and patterns of relapse in patients with bilateral Wilms tumor or bilaterally predisposed unilateral Wilms tumor, a report from the COG AREN0534 study. PMID 38973574 · Int J Cancer · 2024-Nov-15 The study is a Phase III oncology trial with a primary time-to-event efficacy endpoint (EFS) and reports original results. However, it cannot be confirmed as eligible because the abstract does not explicitly state that the trial was randomized or that a specific drug-containing intervention (vs. non-drug or standard-of-care) was compared. The deterministic review flagged unclear randomization evidence.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Clinical Impact of Contouring Variability for Prostate Cancer Tumor Boost. PMID 38925224 · Int J Radiat Oncol Biol Phys · 2024-Nov-15 The record describes a secondary analysis evaluating the impact of contouring variability on predicted outcomes in the context of a Phase III RCT. While it references a randomized trial and a time-to-event endpoint (biochemical failure), it does not meet the eligibility criteria because it is not an original report of a drug intervention trial with Kaplan-Meier or HR efficacy results. The intervention is radiation therapy planning, not a drug, and the study is a secondary analysis, not the primary trial report.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -